MiMedx Group (NASDAQ:MDXG) Hits New 12-Month Low – Here’s What Happened

MiMedx Group, Inc (NASDAQ:MDXG) hit a new 52-week low during trading on Wednesday . The company traded as low as $5.65 and last traded at $5.7040, with a volume of 235734 shares changing hands. The stock had previously closed at $5.88.

Wall Street Analysts Forecast Growth

A number of analysts have commented on MDXG shares. Wall Street Zen upgraded shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of MiMedx Group in a report on Monday, December 29th. Finally, Mizuho lowered their price objective on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 17th. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

MiMedx Group Stock Down 3.7%

The stock has a market capitalization of $838.99 million, a price-to-earnings ratio of 20.98 and a beta of 1.57. The business has a 50-day moving average of $6.91 and a 200-day moving average of $6.93. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, October 29th. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.07 by $0.08. The company had revenue of $113.73 million during the quarter, compared to analyst estimates of $94.74 million. MiMedx Group had a net margin of 10.38% and a return on equity of 27.19%. On average, sell-side analysts expect that MiMedx Group, Inc will post 0.3 EPS for the current year.

Insider Buying and Selling

In other MiMedx Group news, insider Kimberly Maersk-Moller sold 58,300 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $7.42, for a total transaction of $432,586.00. Following the transaction, the insider directly owned 236,982 shares in the company, valued at $1,758,406.44. This represents a 19.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On MiMedx Group

Several hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC grew its position in MiMedx Group by 16.1% in the 4th quarter. SG Americas Securities LLC now owns 188,045 shares of the company’s stock valued at $1,273,000 after acquiring an additional 26,085 shares in the last quarter. Tudor Investment Corp ET AL purchased a new position in shares of MiMedx Group in the third quarter valued at approximately $487,000. CIBC Bancorp USA Inc. acquired a new position in shares of MiMedx Group in the third quarter valued at approximately $88,000. Dark Forest Capital Management LP acquired a new position in shares of MiMedx Group in the third quarter valued at approximately $104,000. Finally, PharVision Advisers LLC purchased a new stake in MiMedx Group during the 3rd quarter worth approximately $121,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.